Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
NCT02457897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2019-12-05
Summary
Background:
\- Insulin receptor mutation causes high blood sugars and sometimes diabetes complications. Researchers want to see if thyroid hormone helps.
Objectives:
\- To see if thyroid hormone treatment changes how the body handles sugar in people with insulin receptor mutation and improves blood sugar in people with diabetes.
Eligibility:
\- People ages 12 65 with an insulin receptor mutation.
Design:
* Study part 1:19-day clinic stay. Participants will be monitored for 4 days. Then for 15 days they will take a thyroid hormone pill 3 times a day. Participants will have:
* Blood tests.
* Heart rate and skin temperature monitored.
* All their food provided.
* Two 5-hour sessions in a special room. They will wear special clothes and sometimes sit still.
* Two small tubes inserted in veins. One will deliver tiny amounts of sugar and fat with a non-radioactive tracer. Participants will also drink water with a tracer. The other tube will collect blood.
* A sweet drink. Participants may have finger stick blood sugar tests.
* Glucose-monitoring device inserted into body fat for two 24-hour periods.
* Adults may have samples of fat and muscle taken.
* Heart ultrasound.
* PET-CT scan in a machine. An intravenous catheter will be placed in an arm vein. A small amount of radioactive substance will be injected.
* DEXA scan of body fat and bone density.
* Participants with poorly controlled diabetes will then take thyroid hormone at home for 6 months. They will have blood drawn and sent to the study team monthly.
* After about 3 months, they will have an overnight visit. After 6 months, they will have a 4-day visit.
Conditions
- Insulin Resistance
- Diabetes Mellitus
- Abnormal Glucose Metabolism
Interventions
- DRUG
-
Liothyronine
Oral supplement given every 8 hours
Sponsors & Collaborators
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
lead NIH
Principal Investigators
-
Rebecca J Brown, M.D. · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 12 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-17
- Primary Completion
- 2018-09-18
- Completion
- 2018-09-18
Countries
- United States
Study Locations
More Related Trials
-
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
NCT04133922 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Glucagon-like Peptide-1 in Type 1 Diabetes
NCT04355832 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098 ·Status: COMPLETED ·Phase: NA
-
The Effect of Anakinra on Insulin Secretion
NCT01285232 ·Status: UNKNOWN ·Phase: NA
-
GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
NCT01592279 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
NCT05553093 ·Status: RECRUITING ·Phase: PHASE4
-
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
NCT04135287 ·Status: UNKNOWN ·Phase: PHASE4
-
Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance
NCT01173978 ·Status: COMPLETED ·Phase: NA
-
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
NCT00923962 ·Status: COMPLETED ·Phase: NA
-
Effects of Leptin Replacement in Children
NCT00659828 ·Status: COMPLETED ·Phase: PHASE2
-
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT03954873 ·Status: COMPLETED ·Phase: NA
-
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603 ·Status: UNKNOWN ·Phase: NA
-
Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes
NCT06715514 ·Status: RECRUITING ·Phase: NA
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
NCT06976619 ·Status: RECRUITING ·Phase: PHASE2
-
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
NCT01607450 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00862589 ·Status: COMPLETED ·Phase: NA
-
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
NCT00118937 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
NCT05093517 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
NCT02960659 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Studies of Insulin and Glucagon Action in the Liver
NCT07300982 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production
NCT03141827 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597 ·Status: COMPLETED ·Phase: NA
-
The Glucagonotropic Effect of Amino Acids in Humans
NCT05954923 ·Status: COMPLETED ·Phase: NA
-
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
NCT06881472 ·Status: COMPLETED ·Phase: NA